News & Research
New studies, trials, regulatory changes and news about the compounds on Amino Reference. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-05.
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
CNBC
Eloralintide, a selective amylin agonist not in the catalogue, plus tirzepatide produced up to 23.3% weight loss at 48 weeks in obesity with type 2 diabetes, and Lilly plans phase 3 by year-end. The site should flag the new peptide and should not paste the combination result onto tirzepatide monotherapy.
- EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
Pharmacy Times
The same phase 2b of eloralintide plus tirzepatide cut HbA1c by up to 2.9% in adults with obesity and type 2 diabetes. Adverse-event discontinuations were 10.8% to 27% when both drugs were escalated together, which is the tolerability figure to show if the combination is mentioned.